1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Ainos, Inc.

Ainos, Inc.

AIMDW
Ainos, Inc.US flagNASDAQ Global Market
0.13
USD
-0.01
- -
586,796.00Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
1
4
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
-231.05
-1,717.2
-13,472.11
-8,696.7
-650.47
-397.09
-10,814.99
-66,772.17
-11,268.32
-72,393.48
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
2
5
5
5
5
5
Net Income, GAAP
-1
- -
-1
-1
-1
-1
-2
-1
-4
-14
-14
-15
-15
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-246.04
-1,722.3
-13,479.65
-8,758.21
-654.04
-397.96
-11,276.98
-71,702.26
-11,897.04
-76,996.25
Working Capital
-5
- -
-1
-1
- -
1
- -
-1
-28
- -
1
- -
- -
-3
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6
9
11
9
Total Equity
-5
- -
- -
-1
- -
1
- -
-1
10
35
24
16
8
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
5
LT Borrowings
11
11
9
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
6
6
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2
1
4
Cash, Cash Equivalents & STI
1
- -
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
6
Payables & Accruals
1
1
1
ST Debt
- -
- -
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-91.2%
-238.81%
-51.26%
Free Cash Flow
45.95%
74.09%
-20.25%
Net Income, GAAP
58.11%
86.78%
-0.62%
Sales/Revenue/Turnover
- -
860.22%
498.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Chun-Hsien Tsai
Full Time Employees
44
Sector
Healthcare
Industry
Biotechnology
Address
8880 Rio San Diego Drive San Diego TX United States of America 92108
IPO Date
Jan 8, 2021
CIK
0001014763
Website
ainos.com
Similar Companies
Alector, Inc. (ALEC)
SYN-TECH Chem. & Pharm. Co., Ltd. (1777.TWO)
Anthem Biosciences Ltd. (ANTHEM.NS)
Pathfinder Cell Therapy, Inc. (PFND)
MoonLake Immunotherapeutics (MLTX)
Tyra Biosciences, Inc. (TYRA)
Business
Ainos, Inc. (NASDAQ: AIMD; AIMDW) is a dual-platform AI and biotech company that develops and commercializes SmellTech solutions, AI-powered diagnostics, and low-dose interferon-alpha therapeutics. The company offers its proprietary AI Nose platform, which employs a smell language model to digitize scents into machine-readable Smell IDs for applications in volatile organic compound detection, point-of-care testing, semiconductor fabrication, smart factories, robotics, senior care, women's health, hospital infection management, and environmental monitoring; VELDONA, a clinical-stage low-dose oral interferon-alpha targeting rare diseases such as HIV-related oral warts and primary Sjögren’s syndrome, infectious conditions including common cold and influenza, autoimmune disorders, and animal health issues like feline chronic gingivostomatitis, allergies, skin and gum problems, and weight-related discomfort in pets and humans; VOC-based point-of-care tests including Ainos Flora for female vaginal health and sexually transmitted infections, Ainos Pen, and CHS430; and legacy products such as COVID-19 antigen rapid test kits. Headquartered in San Diego, California, and founded in 1984 as Amarillo Biosciences, Inc., which changed its name to Ainos, Inc. in May 2021, the company operates primarily in the United States with global partnerships focused on Asia; it functions as a subsidiary of Taiwan Carbon Nano Technology Corporation and maintains research and development collaborations across healthcare, industrial sensing, and medtech sectors targeting enterprise clients, healthcare providers, and veterinary markets. Recent developments include a $2.1 million three-year subscription-based AI Nose order from ASE Technology Holding Co., Ltd. in 2025; strategic alliances with Topco for global distribution, Kenmec Mechanical Engineering for industrial automation showcased at Automation Taipei and SEMICON Taiwan 2025, ugo for service robots with olfactory capabilities, Solomon Technology Corporation, and Nisshinbo Micro Devices for VOC platform co-development; the debut of the world's first patented portable, cloud-connected AI Nose device with SmellTech-as-a-Service subscriptions; a 1-for-5 reverse stock split effective June 30, 2025; and $1.75 million follow-on funding in early 2024 to support VELDONA investigational new drug preparations and AI Nose advancements.

Company News

APIChat

  • defenseworld.net

    Ainos, Inc. (NASDAQ:AIMDW) Sees Significant Decrease in Short Interest